Akso Pharma proudly participated in the National Dermatology Conference 2026, bringing together dermatologists, healthcare professionals, researchers, and industry leaders from across Nigeria to exchange knowledge and explore the latest developments in dermatological care.
Throughout the conference, the Akso Pharma exhibition stand welcomed a large number of visitors who explored our expanding portfolio of high-quality dermatology and healthcare products designed to meet the evolving needs of healthcare professionals and patients.
Featured Products
During the exhibition, Akso Pharma showcased a range of dermatology solutions, including:
FINASIL® Spray (Terbinafine Hydrochloride 1% w/v) – A convenient topical antifungal spray for the treatment of common fungal skin infections, including athlete's foot, ringworm, and jock itch.
BACTROX® Ointment (Mupirocin) – A topical antibacterial ointment indicated for susceptible bacterial skin infections.
MINATE® Cream (Miconazole Nitrate) – An antifungal cream for the treatment of a variety of superficial fungal skin infections.
AKSOCORT® Cream (Hydrocortisone) – A mild topical corticosteroid for the relief of inflammatory skin conditions and itching.
VARIKS® Cream (Aciclovir) – An antiviral cream used in the management of herpes simplex virus skin infections.
These products attracted strong interest from dermatologists seeking effective, reliable, and affordable treatment options for everyday clinical practice.
Conference Highlight: Scientific Presentation on FINASIL® Spray
One of the key highlights of the conference was a scientific presentation delivered by Dr. Aisha Sokunbi of the University of Benin Teaching Hospital, titled:
"Optimizing the Management of Dermatophytosis: The Role of Topical Terbinafine."
During the session, Dr. Sokunbi emphasized the fungicidal activity of terbinafine, explaining how it differs from many antifungal agents by actively killing dermatophytes rather than merely inhibiting their growth. She also highlighted the clinical advantages of the topical spray formulation, including:
Convenient, touch-free application that minimizes direct contact with infected skin.
Easy coverage of larger or difficult-to-reach affected areas.
Improved patient convenience and treatment adherence.
Fast-drying, non-greasy formulation suitable for Nigeria's hot and humid climate.
Reduced risk of cross-contamination during application.
Dr. Sokunbi also noted that topical terbinafine spray remains a relatively novel dosage form in the Nigerian market, offering healthcare professionals and patients an additional evidence-based treatment option for the management of superficial fungal infections such as athlete's foot, ringworm, and jock itch.
The presentation generated significant interest among conference participants and stimulated valuable discussions on improving antifungal treatment strategies and expanding access to innovative dermatology solutions in Nigeria.
Strengthening Partnerships in Dermatology
The conference provided an excellent platform for Akso Pharma to engage directly with dermatologists, exchange clinical insights, and strengthen relationships with healthcare professionals across Nigeria.
We sincerely thank everyone who visited our booth and participated in discussions throughout the event. Your valuable feedback and support continue to inspire our commitment to delivering trusted pharmaceutical solutions that improve patient care.
As Akso Pharma continues to expand its dermatology portfolio, we remain dedicated to supporting healthcare professionals through innovation, quality products, scientific education, and long-term partnerships.
